Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Perindopril Generic Name & Formulations
Legal Class
Rx
General Description
Perindopril erbumine 2mg, 4mg, 8mg; scored tabs.
Pharmacological Class
ACE inhibitor.
How Supplied
Contact supplier
Manufacturer
Perindopril Indications
Indications
To reduce risk of cardiovascular mortality or nonfatal MI in patients with stable coronary artery disease.
Perindopril Dosage and Administration
Adult
Initially 4mg once daily for 2 weeks, then increase as tolerated; maintenance: max 8mg once daily. Elderly (>70yrs): initially 2mg once daily for 1st week, then 4mg once daily for 2nd week; maintenance: 8mg once daily, if tolerated. Renal impairment: CrCl <30mL/min: not recommended; CrCl ≥30mL/min: initially 2mg/day: max 8mg/day.
Children
Not established.
Perindopril Contraindications
Contraindications
History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes. Concomitant neprilysin inhibitor (eg, sacubitril); do not give within 36 hours of switching to or from sacubitril/valsartan.
Perindopril Boxed Warnings
Boxed Warning
Fetal toxicity.
Perindopril Warnings/Precautions
Warnings/Precautions
Fetal toxicity may develop: discontinue if pregnancy is detected. Salt/volume depletion. Dialysis. Severe CHF. Renal artery or aortic stenosis. Monitor BP, electrolytes, and renal function periodically. Diabetes. Monitor for neutropenia in renal or collagen vascular disease (eg, SLE). Hepatic impairment. Surgery. Discontinue if laryngeal edema, angioedema (have SC epinephrine available), marked elevations of liver enzymes or jaundice occurs. Black patients may have higher risk of angioedema than non-black patients. Elderly. Neonates. Pregnancy (Cat.D); avoid. Nursing mothers.
Perindopril Pharmacokinetics
See Literature
Perindopril Interactions
Interactions
See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes, others (eg, cyclosporine, indomethacin, heparin). Excessive hypotension with diuretics. May increase lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function in elderly and/or volume-depleted). Caution with gentamicin, digoxin. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Perindopril Adverse Reactions
Adverse Reactions
Headache, cough, dizziness, back pain, drug intolerance, hypotension, fever; hyperkalemia.
Perindopril Clinical Trials
See Literature
Perindopril Note
Notes
Formerly known under the brand name Aceon.
Perindopril Patient Counseling
See Literature
Perindopril Generic Name & Formulations
Legal Class
Rx
General Description
Perindopril erbumine 2mg, 4mg, 8mg; scored tabs.
Pharmacological Class
ACE inhibitor.
How Supplied
Contact supplier
Manufacturer
Perindopril Indications
Indications
Hypertension.
Perindopril Dosage and Administration
Adult
If not on diuretic: initially 4mg once daily; may increase to max 16mg/day. Usual maintenance 4–8mg as a single daily dose or in two divided doses. If on diuretic: consider reducing diuretic dose prior to starting therapy. Elderly: usual max 8mg/day. Renal impairment: CrCl <30mL/min: not recommended; CrCl ≥30mL/min: initially 2mg/day: max 8mg/day.
Children
Not established.
Perindopril Contraindications
Contraindications
History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes. Concomitant neprilysin inhibitor (eg, sacubitril); do not give within 36 hours of switching to or from sacubitril/valsartan.
Perindopril Boxed Warnings
Boxed Warning
Fetal toxicity.
Perindopril Warnings/Precautions
Warnings/Precautions
Fetal toxicity may develop: discontinue if pregnancy is detected. Salt/volume depletion. Dialysis. Severe CHF. Renal artery or aortic stenosis. Monitor BP, electrolytes, and renal function periodically. Diabetes. Monitor for neutropenia in renal or collagen vascular disease (eg, SLE). Hepatic impairment. Surgery. Discontinue if laryngeal edema, angioedema (have SC epinephrine available), marked elevations of liver enzymes or jaundice occurs. Black patients may have higher risk of angioedema than non-black patients. Elderly. Neonates. Pregnancy (Cat.D); avoid. Nursing mothers.
Perindopril Pharmacokinetics
See Literature
Perindopril Interactions
Interactions
See Contraindications. Increased risk of angioedema with concomitant neprilysin inhibitor or mTOR inhibitor (eg, temsirolimus). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes, others (eg, cyclosporine, indomethacin, heparin). Excessive hypotension with diuretics. May increase lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function in elderly and/or volume-depleted). Caution with gentamicin, digoxin. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Perindopril Adverse Reactions
Adverse Reactions
Headache, cough, dizziness, back pain, drug intolerance, hypotension, fever; hyperkalemia.
Perindopril Clinical Trials
See Literature
Perindopril Note
Notes
Formerly known under the brand name Aceon.
Perindopril Patient Counseling
See Literature
